A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Melanoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Renal Cell Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Last updated on ClinicalTrials.gov
- December 19, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, San Francisco (UCSF) · San Francisco, CA
Florida · 2
- Ocala Oncology Center · Ocala, FL
- BRCR Medical Center · Plantation, FL
Kansas · 1
- University of Kansas Medical Center (KUMC) · Fairway, KS
Michigan · 2
- Michigan Hematology & Oncology Consultants - MedOnc Dearborn · Dearborn, MI
- Michigan Hematology & Oncology Consultants - MedOnc Troy · Troy, MI
Texas · 2
- MD Anderson Cancer Center-University of Texas · Houston, TX
- Oncology Consultants P.A. · Houston, TX
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.